Synthetic hypericin
Small molecule
Evidence outlook · registrational
Topline reported 2026-04-28
Its supporting mid-stage studies have completed. The sponsor reported topline results on 2026-04-28 (FLASH2 Phase 3 interim analysis: halted for futility). The announcement is listed under Regulatory events.
Development in Cutaneous T-Cell Lymphoma stopped (2026-06) after a negative readout. Development continues in another indication. Source
Development in Psoriasis stopped (2026-11-06) for financing reasons. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02448381 NCT02448381 · Cutaneous T-Cell Lymphoma This was a randomized, quadruple-blind, placebo-controlled trial with 169 participants and a clinical lesion-severity endpoint based on the CAILS score. The primary endpoint was met, with significantly more participants responding to SGX301 than placebo at 8 weeks. Registry: NCT02448381 | 3 | Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score When Compared to Patients Receiving Placebo (8 weeks) 2020-06 | Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score When Compared to Patients Receiving Placebo (8 weeks): SGX301 — Responder: 19 Participants; Non-responder: 97 Participants | Placebo — Responder: 2 Participants; Non-responder: 48 Participants | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent